Summit Therapeutics Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On November 15, 2026, the FDA issued a Complete Response Letter (CRL) for Summit's ivonescimab BLA in EGFR-mutated NSCLC, stating that substantial evidence of effectiveness is not established due to failure to achieve statistically significant overall survival (OS) improvement in the primary analysis, despite meeting the progression-free survival (PFS) primary endpoint. The HARMONi Phase III study showed ivonescimab + chemotherapy demonstrated positive OS trends and OS benefits in post-hoc regional analyses (HR 0.76), but these did not meet the FDA's regulatory threshold; the company continues development across five Phase III programs and multiple collaborative trials despite this setback.
Why this rating
Major regulatory setback for lead program; ivonescimab was a cornerstone asset. CRL materially delays/jeopardizes U.S. approval pathway, though drug approved in China and pipeline remains active. Relative to $2.5B market cap, loss of near-term NSCLC approval is substantial; however, company retains multiple ongoing trials and partnerships, partially offsetting impact.
Tradability signal
SHORT
conviction 37/100 · expected -1.49% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (108 in this cell) moved +1.84% in the called direction over 4 hrs; shrunk for sample size that's a +1.49% edge. Price is up 16.0% since the filing hit EDGAR — market hasn't digested it yet. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $11.30 ▼ 10.43% | at our read · unknown $12.62 | +10 min · unknown $12.67 ▲ 0.44% | +30 min · unknown $12.81 ▲ 1.54% | +1 hr · unknown $12.37 ▼ 1.95% | +4 hrs · unknown $11.95 ▼ 5.29% |
The stock had already moved +11.65% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.